Dissertations / Theses on the topic 'Médicaments de l'appareil cardiovasculaire'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 37 dissertations / theses for your research on the topic 'Médicaments de l'appareil cardiovasculaire.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Sors, Martine. "Médicaments cardiovasculaires et conseil du malade à l'officine." Lyon 1, 1990. http://www.theses.fr/1990LYO1P123.
Full textGaillard, Alain. "Tentative d' étude des effets de la sympathectomie lombaire : à propos de l' évolution suivie chez 47 sujets." Clermont-Ferrand 1, 1987. http://www.theses.fr/1987CLF11030.
Full textChalon, Stephan. "Dysfonction endothéliale veineuse induite par le tabac chez l'homme : approche pharmacologique." Paris 11, 2000. http://www.theses.fr/2000PA11T018.
Full textFornès, Paul. "La mort subite coronaire, étude histologique et histomorphométrique des artères coronaires et du myocarde : Etude portant sur 111 autopsies." Paris 6, Saint-Antoine, 1991. http://www.theses.fr/1991PA062012.
Full textHogie, Manuela. "Rôle de l'endothéline endogène dans le contrôle du tonus vasculaire dans des situations physiologiques ou physiopathologiques." Rouen, 1998. http://www.theses.fr/1998ROUES088.
Full textOddon, Pascal. "Intoxication médicamenteuse volontaire par absorption de drogues cardiotropes (celiprolol, diltiazem et isosorbide dinitrate) : à propos d'un cas." Montpellier 1, 1997. http://www.theses.fr/1997MON11012.
Full textNicolle, Edwige. "Nouvelles thiazolidino [3,2-a] pyrimidines : synthèse, étude structurale et pharmacologique." Université Joseph Fourier (Grenoble), 1990. http://www.theses.fr/1990GRE18007.
Full textWu, Wen. "Développement de nanoparticules composites polymériques de S-nitrosoglutathion dédiés au traitement oral des maladies cardiovasculaires." Thesis, Université de Lorraine, 2015. http://www.theses.fr/2015LORR0115.
Full textAs a physiologic nitric oxide (NO) donor, S-nitrosoglutathione (GSNO) has potential therapeutic application for the treatment of cardiovascular disease (CVD). With a longer in vivo half-life than NO, GSNO is still sensitive to many factors leading to poor applicability. This study aimed at the development of nanocomposite particles (NCP) based on synthetic polymeric nanoparticles encapsulating GSNO (GSNO-NP) embedded in a polysaccharidic matrix for oral delivery of GSNO. Although GSNO-NP, with a high encapsulation efficiency, showed an in vitro burst release, they succeeded in the preservation of GSNO stability and bioavailability for smooth muscle cells as they delayed in vitro protein S-nitrosation (NO biomarker) until 18 h. Therefore, to reach the sustained release, GSNO-NP were embedded in a matrix of alginate (a), chitosan (c) or a blend (acNCP). GSNO-acNCP with high encapsulation efficiency (76%) and an in vitro release until 24 h, promoted the highest permeation rate of GSNO through an intestinal barrier model (Caco-2). With this daily oral treatment compatibility Wistar Rat pretreatment by gavage with GSNO-acNCP 17 h before aorta removal decreased the maximal contractile effect induced by phenylephrine (PHE) on isolated aortic rings. Furthermore, the N-acetylcysteine (a thiol displacing NO stores from tissues) produced the relaxation of PHE precontracted aortic rings, proving NO storage in the vessel wall. By increasing the residence time in the gastrointestinal tract thus promoting GSNO crossing through the intestinal barrier, GSNO-acNCP induced a long lasting effect (17 h after administration) through NO storage in vessels
Di, Prizio Stéphane Gueffet Jean-Pierre. "Iatrogénie du traitement du post-infarctus chez le sujet de plus de 70 ans." [S.l.] : [s.n.], 2007. http://castore.univ-nantes.fr/castore/GetOAIRef?idDoc=24011.
Full textMoins, Nicole. "Étude pharmacologique d'un ionophore monocarboxylique, la grisorixine : effets sur l'appareil cardiovasculaire et le métabolisme cardiaque." 63-Aubière : Impr. U.E.R. Sci, 1985. http://catalogue.bnf.fr/ark:/12148/cb36110211s.
Full textDelahaye, Catherine. "Incidents et accidents imputables aux médicaments à visée cardiovasculaire : enquête de 3 mois dans le service de cardiologie de l'hôpital Beaujon." Paris 5, 1988. http://www.theses.fr/1988PA05P189.
Full textRichard, Carole. "Etude de la toxicité cardiaque des médicaments anti-cancéreux." Phd thesis, Université de Bourgogne, 2011. http://tel.archives-ouvertes.fr/tel-00938753.
Full textZhou, Yi. "Mechanisms of S-nitrosothiols intestinal permeability and NO store formation within vascular wall to improve NO oral delivery systems." Thesis, Université de Lorraine, 2019. http://www.theses.fr/2019LORR0101/document.
Full textS-nitrosothiols (RSNOs) such as S-nitrosoglutathione (GSNO) are promising nitric oxide (NO) donors for cardiovascular diseases treatment. However, they are poorly stable drug candidates. In previous studies, GSNO-loaded nanoparticles (GSNO-NP) were embedded into an alginate/chitosan matrix. Resulting nanocomposite particles showed high encapsulation and sustained release of GSNO, and led to the formation of a NO store in the wall of aorta after a single oral administration to rats. However, these nanocomposite particles have several limitations such as time-consuming preparation, lack of both stability and reproducibility. This thesis work aimed at: 1) Elucidate the mechanism of free RSNOs intestinal absorption; 2) Evaluate ability of free RSNOs to form a vascular NO store; 3) Optimize the GSNO formulation. In this study, we showed that the intestinal permeability (in vitro model of intestinal barrier) of GSNO, S-nitroso-N-acetylcysteine (NACNO) and S-nitroso-N-acetylpenicillamine (SNAP) was a passive diffusion, following the transcellular pathway (and also the paracellular way for SNAP) and belonging to the medium permeability class. After crossing the intestinal barrier, RSNOs will reach the vasculature. In order to compare the ability of free RSNOs to form a vascular store of NO either in endothelium-intact or endothelium-removed aortae, we quantified the store, verified its bioavailability for vasorelaxation and evaluated its impact on phenylephrine (PHE)-induced vasoconstriction. Incubation with RSNOs increased the basal NO store three to five times. This store is still bioavailable to induce vasorelaxation and efficient to induce vascular hyporeactivity to PHE (NACNO> GSNO = SNAP) only in endothelium-removed aortae. As intestinal permeability of RSNOs was in the medium class, the integration of GSNO into an appropriate delivery system is essential. Limitations of previously developed nanocomposites particles were impossible to bypass so the production process of GSNO-NP was modified (liquid or solid GSNO in the internal phase of the emulsion) to produce microparticles. Both kinds of microparticles exhibited a slower release of GSNO than GSNO-NP. Nano-and micro-particles were stable after lyophilization and presented an enhancement of GSNO intestinal permeability (up to high permeability class for microparticles). Thus, oral administration of GSNO/RSNO loaded nano/micro particles seems to be a promising avenue for the treatment of cardiovascular diseases
Leclerc, Jacinthe. "Surveillance des consultations à l'urgence et des hospitalisations chez les utilisateurs de médicaments génériques et originaux en cardiologie, au Québec." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/28236.
Full textDrugs have a prominent place in cares of cardiovascular diseases. Several pharmaceutical options are currently available in Quebec. Among those, generic drugs constitute the economical alternative when the brand-name drug’s patent expires. Drug insurance plans give priority to the reimbursement of generic drugs once available, being on average three times more economical than the corresponding brand-name drug. In recent years, health care professionals and their patients have raised concerns about the safety (adverse drug reactions) and efficacy of generic drugs. This suggests that not only the price that differs between generic and brand-name drugs. Article 1 presents a literature review aimed at understanding the actual differences between generic and brand-name drugs. Beyond the price, generic drugs are distinct products from their brand-name counterparts, and vary in terms of 1) commercial name, 2) inactive ingredients and, 3) licensing processes. In that respect, Canadian government standards regulate the bioequivalence of generic drugs. To meet health authority norms and being considered bioequivalent to their brand-name drug, some pharmacokinetics parameters of generic versions should generally stand within 20% compared to their brand-name reference drug. Although modest, these bioavailability differences between brand-name and their generic drugs are documented in respective generic product monographs. In the literature, whether bioequivalence of generics versus brand-name drugs translates into clinical equivalence at a population level is not clear. Based on this hypothesis, we aimed to evaluate if adverse events would differ between brand-name and generic users, once generic versions became available on the market. Articles 2 and 3 present studies whose purpose is to evaluate the impact of generic drugs commercialization on adverse events (all causes emergency room consultations or hospitalizations), compared to brand-name versions. To this end, we included all Quebecers aged 66 years and over treated with drugs widely used in the field of hypertension, ischemic heart disease or heart failure: losartan, valsartan, candesartan and clopidogrel. With a time series analysis using linked health administrative data from the Quebec Integrated Chronic Disease Surveillance System, we estimated monthly rates of adverse events that occurred over a three-year period, two years before and up to one year after respective first generic drug commercialization. A total of 136,177 patients using losartan, valsartan or candesartan are included in article 2. This number was 89,525 patients using clopidogrel in article 3. In both articles, adverse event rates were stable before the arrival of the generic versions and remained unchanged after, in the entire population. However, if we look at the rates of generic users only, the results revealed an immediate increase in adverse events, reproducible for the four studied drugs. Adverse event rates were also consistently higher among users of generic versions compared to users of the corresponding brand-name version over one year after generics commercialization. Many additional analyses were conducted by stratification for patients’ characteristics. Differences of adverse events between generic and brand-name users were similarly found in patients with 3 to 4 cardiovascular comorbidities or more compared to their lower stratum, as well as in patients of different socio-economic status. The effect was similar between male and female clopidogrel users as well. It was already known that generic drugs differed from their brand-name equivalent in terms of costs. Not only can they vary with respect to their bioavailability compared to the brand-name version, we observed that health outcomes associated with the use of generic drugs may not be entirely identical to health outcomes in patients using the brand-name drug. This could be explained by the substitution to a generic version with different bioavailability, but also, at least in part, due to other factors that were not measured in this study. The detection of this pharmacovigilance signal deserves in-depth clinical investigation, if possible, beyond health administrative data, to characterize properly the impact of generic drug substitutions. Going back to patients’ medical charts would permit to characterize clearly the clinical impact of generic drugs substitutions. It is possible that Health Canada's standards for licensing generic drug need to be revisited if those results are confirmed by other jurisdictions or health care systems.
Dillinger, Jean-Guillaume. "Mécanismes et déterminismes de la résistance biologique aux antiagrégants plaquettaires dans la pathologie cardiovasculaire." Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCC117.
Full textThe occurrence of cardiovascular events under antiplatelet treatment, showing a persistence of atherothrombotic phenomena is behind the concept of "resistance" to antiplatelet agents. The aim of this work was to characterize and understand some basic mechanisms of "resistance" to aspirin but also to ADP inhibitors. The biological resistance of antiplatelet drugs is often the result of either a pharmacokinetic disruption of the antiplatelet drug (absorption, distribution, and metabolism) with insufficient blood level of the active metabolite, or a modified pharmacodynamics of the drug. Concerning high platelet reactivity under aspirin, it seems clearly linked to platelet turnover. A depletion of platelet inhibition during the day was clearly identified in some patients (essential thrombocythemia, diabetes) but also in some circumstances (acute coronary syndrome, inflammation. . . ). The measurement of surrogate markers of accelerated platelet turnover, thrombopoietin for example, confirms this mechanism. The distribution of aspirin doses during the day improved platelet inhibition and thus could be an interesting alternative for better protection. Concerning clopidogrel, the importance of hepatic cytochrome polymorphism has helped explain much of high platelet reactivity under this treatment. The drug interactions and gastrointestinal absorption are important mechanisms of high platelet reactivity under new inhibitors of ADP
Morizot, Sylvie. "Etude sur une population jeune et en bonne santé des effets d'un bruit de trafic routier, d'une benzodiazépine, et de leur conjugaison, sur les potentiels évoqués auditifs précoces, l'appareil cardiovasculaire et l'anxiété." Dijon, 1998. http://www.theses.fr/1998DIJOS011.
Full textDubreuil, Marc. "Cardiotoxicité de la Bupivacai͏̈ne : étude hémodynamique in vivo chez le rat." Bordeaux 2, 1992. http://www.theses.fr/1992BOR23004.
Full textLaurant, Pascal. "Etude des effets de la surcharge chronique en magnésium sur le fonctionnement de l'appareil cardiovasculaire au cours de l'hypertension minéralocorticoi͏̈de DOCA + NaCl chez le rat mâle." Besançon, 1990. http://www.theses.fr/1990BESA3702.
Full textMathias, Christine. "Mise en évidence de l'induction enzymatique hépatocytaire : aspects méthodologiques et application pratique." Aix-Marseille 2, 1991. http://www.theses.fr/1991AIX20020.
Full textSirois, Caroline. "Qualité du traitement cardioprotecteur du diabète de type 2 chez les aînés québécois et son impact sur la morbidité cardiovasculaire." Thesis, Université Laval, 2010. http://www.theses.ulaval.ca/2010/27375/27375.pdf.
Full textGranger, Isabelle. "Recherche de molécules d'origine végétale à visée cardiovasculaire présentant une affinité pour les récepteurs V1a de la vasopressine." Toulouse, INPT, 1993. http://www.theses.fr/1993INPT034G.
Full textDuckert, Jean-Frédéric. "Synthèses de mimes non peptidiques du glutathion, précurseurs d'analogues du leucotriène C4." Montpellier 2, 2002. http://www.theses.fr/2002MON20037.
Full textScailteux, Lucie-Marie. "Evaluation de la sécurité d’emploi des médicaments modulant les androgènes dans les maladies prostatiques, une approche pharmaco-épidémiologique." Thesis, Rennes 1, 2017. http://www.theses.fr/2017REN1B006.
Full textContext: In France, prostate cancer is a frequent disease in elderly men, and the first cause of cancer. It is associated with a 70 % survival at 10 years. Different therapeutics options are recommended in prostate cancer management, including hormonotherapy (or androgen deprivation therapy, ADT). Safety of ADT modalities is challenged since mid of 2000’s when some authors evoked an increased cardiovascular risk in ADT-treated patients compared to non-treated patients. Results of these studies appeared conflicting, and heterogeneity of cardiovascular risk across ADT modalities was evoked but not directly investigated. Objective: Our aim was to assess the hypothesis of qualitative heterogeneity across the different ADT modalities used for prostate cancer. Methods: Through a new approach compared to previously published studies, we firstly conducted a direct and network meta-analysis of both randomized controlled trials and observational studies, “METADTCR”, comparing ischemic cardiovascular morbidity, mortality and overall death across the different ADT modalities. Secondly, we set up a population-based cohort study, “ADTCR”, using French Health Insurance database (SNIIRAM/DCIR) linked to hospital reimbursement data (PMSI), including men with prostate cancer who initiated an ADT, and measuring the occurrence of ischemic diseases (myocardial infarction or ischemic stroke). Results – Conclusion: As regards METADTCR, randomized controlled trials gave too few data related to cardiovascular morbidity and mortality; observational studies meta-analysis suffered from substantial inconsistency and eventually the question of cardiovascular risk morbidity and mortality remained. In ADTCR, a heterogeneous risk of ischemic events was observed across ADT modalities: compared to GnRH agonists, an increased risk of ischemic events was identified with combined androgen blockade, and a decrease risk with anti-androgen alone. The most interesting comparison concerned GnRH antagonist: no statistically significant difference was observed. Pharmacological plausibility for a potential increased risk of ischemic events between GnRH agonists and antagonist is not convincing to date and the hypothesis of no risk difference might be true. These results add valuable information to the French and European guidelines for prostate cancer management as regards the safety profile of the different ADT modalities in term of short term ischemic events onset (< 2 years)
Boulenc, Xavier. "Utilisation de la lignée cellulaire humaine colique Caco-2 pour l'étude du métabolisme et de l'absorption des xénobiotiques au niveau intestinal." Montpellier 2, 1994. http://www.theses.fr/1994MON20133.
Full textVillain, Cédric. "Evaluation de la protection cardiovasculaire et rénale chez les sujets âgés atteints de maladie rénale chronique." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLV060.
Full textChronic kidney disease (CKD) prevalence is about 11% but rises up to 30% in people aged ≥70 years. We used data from the CKD REIN cohort study to assess the impact of age on the management of CKD-related cardiovascular disease (CVD) and renal protection. This study included 3033 patients with CKD stage 3-4 recruited in 40 French nephrology departments (mean age 66.8 years, 65% men). The overall prevalence of CVD was 48%, with similar prevalence ratio of atheromatous vs non-atheromatous CVD across age groups, except in patients aged ≥85 years where non-atheromatous CVD predominated. In patients aged <65 years, 29% had at least one CVD as compared to 75% in those ≥85 years. Older age was associated with underuse of renin-angiotensin system (RAS) inhibitors [adjusted odds ratio (aOR) (95% confidence interval) =0.39 (0.16-0.89) for patients aged ≥85 years, compared to those <65 years], beta-blockers [aOR=0.31 (0.19–0.53) for age 75–84 years] and lipid-lowering therapy [p for trend=0.01] in coronary artery disease, but not of antithrombotic drugs as recommended in several CVD. Finally, use of RAS inhibitors was associated with a decrease in the combined risk of death or end-stage CKD [Hazard ratio (HR)=0.79 (0.64-0.98) with propensity score analysis, p for interaction with age =0.56] but not with the risk of hospitalization for acute kidney injury and hyperkalemia [HR=0.73 (0.51-1.06), p for interaction =0.14]. In conclusion, this thesis pointed out the burden of CVD affecting older CKD patients and the gap between guidelines and practices in the management of CVD in these patients. We also provide evidence for the use of RAS inhibitors in older CKD patients
Lemaire, Laurent. "Etude par résonance magnétique nucléaire du fluor-19 de la cardiotoxicité d'un médicament antitumoral majeur, les 5-fluorouracile." Toulouse 3, 1993. http://www.theses.fr/1993TOU30150.
Full textJimenez, Vincent. "Pansements gastriques anti-acides : automédication et influences sur les traitements associés." Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P010.
Full textBertolino, Frédéric. "Caractérisation et modulation pharmacologiques d'effets cardiovasculaires aigus liés à l'activation du récepteur au thromboxane A2/endopéroxyde." Bordeaux 2, 1995. http://www.theses.fr/1995BOR28355.
Full textBejan-Angoulvant, Theodora. "Analyse de la réduction du risque cardiovasculaire par le traitement antihypertenseur : vers une prescription personnalisée." Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10232.
Full textAntihypertensive treatment (AHT) reduces cardiovascular risk (CVR). Its efficacy is well established from numerous clinical trials and meta-analysis conducted in several populations. The AHT effect follows on average a multiplicative model. This model is different from one drug class to another, and is not constant during follow-up.In order to progress towards a personalized prescription of AHT, we followed 3 objectives: 1) The statistical modelling of AHT effect on stroke (ST) and myocardial infarction (MI) in different sub-groups of patients,depending on time of follow-up and first line drug class. 2) The meta-analysis of AHT effect on the risk of stroke,MI and total mortality in patients ages 80 years and older in whom AHT is frequently prescribed. 3) The set-up,conduct and coordination of the IDEAL study, a cross-over randomized double blind clinical trial in order to assess the influence of individual characteristics on blood pressure (BP) response to two AHT drug classes. The first two analyses were performed on the INDANA database, an individual patient data meta-analysis from trials that evaluated the effect of AHT against placebo. These analyses suggest that the decreased benefit of AHT over timeon MI prevention was mostly apparent in women and with first line beta-blocker. Treatment remained efficient invery old patients in reducing CVR, but the lack of mortality reduction led us not to recommend AHT intensificationin this age group. The IDEAL study included 124 patients for which the regression to the mean and the evolution under placebo phenomena explained a BP reduction similar to the one under AHT
Sharma, Ashish. "Gender specific modulation of metoprolol pharmacokinetics and pharmacodynamics." Thesis, Université Laval, 2003. http://www.theses.ulaval.ca/2003/20990/20990.pdf.
Full textLacombe, Olivier. "L'absorption intestinale des xénobiotiques : caractérisation chez le rat." Toulouse 3, 2005. http://www.theses.fr/2005TOU30045.
Full textThe intestinal absorption and metabolism of drugs has been studied in the rat. Using the everted gut sac, a complimentary method to the Caco-2 system, a correlation (r2=0. 91) between the fraction absorbed (Fabs) in vivo and the apparent permeability (Papp) of molecules absorbed by passive diffusion was observed. The Papp of most compounds was 2-3 times lower in the duodenum and ileum than in the jejunum, with the exception of digoxin, which showed a decreased absorption down the intestine, consistent with an increasing activity of P-glycoprotein (P-gp). Five CYP450 activities were characterised using an optimised preparation of intestinal microsomes, and a comparison of the metabolic activities between the microsomes and everted sacs highlighted the importance of the transcellular absorption. The specific activities of hepatic CYP450 enzymes were higher than those of the small intestine. More than 80% of the intestinal activity was located in the upper half of the jejunum
Boucherie, Véronique. "Etudes cliniques, l'harmonisation ? : analyse des recommandations à partir d'un exemple en pathologie cardio-vasculaire." Paris 5, 1995. http://www.theses.fr/1995PA05P219.
Full textGondouin, Bertrand. "Les toxines urémiques provoquent un phénotype procoagulant de l'endothelium par la voie du facteur de transcription AHR." Thesis, Aix-Marseille, 2013. http://www.theses.fr/2013AIXM5054/document.
Full textChronic kidney disease (CKD) is associated with significant morbidity and cardiovascular mortality, which involves chronic inflammation, oxidative stress and endothelial dysfunction. CKD patients have a higher risk of venous or arterial thrombosis compared to general population. Uremic toxins are molecules that accumulate in the serum and organs of CKD patients. Among them, protein-bound uremic toxins are poorly removed by dialysis, and their endothelial toxicity had been well demonstrated in vitro. In this thesis, we demonstrated that indoxyl sulfate (IS) and indole acetic acid (IAA ), two protein-bound toxins can cause a pro coagulant phenotype of cultured endothelial cells through an increased production of tissue factor (TF ) Tissue factor is a membrane procoagulant factor that initiates the coagulation cascade by activating factor VII via the extrinsic pathway. We also demonstrated that TF increase was produced via a cellular pathway previously known to be involved in the detoxification processes: the aryl hydrocarbon receptor pathway (AHR) . The canonical ligand of AHR is dioxin, well known for its cardiovascular adverse effects. In this work, we showed that IS and IAA had a “dioxin- like effect”. The link between FT and AHR had never been shown earlier. CKD constitutes an endogenous situation similar to dioxin poisoning. In conclusion, the IS and IAA are involved in endothelial dysfunction in CKD patients and cardiovascular mortality by increasing the endothelial production of TF and thus causing a pro- coagulant phenotype of endothelial cells. AHR pathway is a very interesting therapeutic target in the problematic of cardiovascular mortality in CKD patients
Kaboré, Jean. "Hypertension artérielle résistante et maladie rénale chronique : déterminants et risques associés." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS265/document.
Full textResistant hypertension and chronic kidney disease: Determinants and outcomesResistant hypertension defined as blood pressure above goal despite simultaneous use of 3 antihypertensive classes at optimal doses including a diuretic, is commonly associated with chronic kidney disease (CKD). Resistant hypertension prevalence and determinants, and the impact of CKD on its long term outcomes are poorly known, particularly in the elderly population.In the 3 Cities cohort, including 4262 community-dwelling elderly individuals, aged 65 years or older treated for hypertension, the prevalence of apparent treatment resistant hypertension (aTRH) – because of lack of information on optimal treatment dose – was 11.8% vs 5.2% in those with vs without CKD (defined as estimated glomerular filtration rate < 60 mL/min/1.73 m2). We showed that new-onset aTRH was more strongly related to the speed of kidney function decline than kidney function level itself, independent of other risk factors: male sex, obesity, diabetes, and history of cardiovascular disease. Compared to the reference group (with controlled hypertension and no CKD), participants with aTRH and CKD had no significantly higher risk of all-cause mortality, but had a risk of fatal or non-fatal stroke and of recurrent stroke or coronary events more than twice as high, and of coronary death more than three times higher. However, the hypothesis that CKD may worsen the prognosis of aTRH was not confirmed (no significant interaction).In the CKDREIN cohort, which included more than 3000 nephrology outpatients with moderate or severe CKD (mean age, 70 years, 60% of men), our preliminary results showed a high prevalence of aTRH, 36,7% and several potentially modifiable risk factors : poor treatment adherence, lack of diuretic use, excess salt intake and obesity.Overall, this work shows the importance of CKD in the development of aTRH and associated cardiovascular outcomes, and suggests means for prevention beyond drug therapy
Bopp, Claire. "Etude expérimentale évaluant l’effet de l’urapidil sur le tonus artériel et sa capacité à préserver la vasoconstriction hypoxique dans l’artère pulmonaire." Thesis, Strasbourg, 2017. http://www.theses.fr/2017STRAJ098/document.
Full textUrapidil, a vasodilator, is widely used in the treatment of hypertension mostly due to better patient tolerance. Urapidil has a dual action: firstly it works as a selective alpha1- adrenoreceptor antagonist and secondly as an agonist of 5-HT1A receptors in the central nervous system. Thus, the present findings, while confirming that urapidil is a potent inhibitor of alpha 1-adrenoceptor-induced contraction targeting preferentially arteries with an endothelial dysfunction, do not support the role of 5-HT1A receptor activation in the control of the vascular tone in response to urapidil in the three types of blood vessels studied. In conclusion, this trial showed that in our experimental setting, urapidil preserved the hypoxia triggered vasoconstriction in isolated pulmonary vessels. Conversely, both calcium channel inhibitors nicardipine and clevidipine blunted the vasocontrictor reaction to hypoxia. These findings may have important clinical consequences that deserve further evaluation
Rebucci, Magali. "Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures." Phd thesis, Université du Droit et de la Santé - Lille II, 2010. http://tel.archives-ouvertes.fr/tel-00576444.
Full textArellano, Michel. "Cardiotoxicité du 5-fluorouracile, médicament antitumoral majeur : mise en cause de la formulation et de la métabolisation." Toulouse 3, 1995. http://www.theses.fr/1995TOU30228.
Full text